Bone-compatible bone substitute

By integrating strontium, fluorine, and/or gallium ions into apatite structures within bone graft materials, the method enhances osteoinductive properties for sustained bone healing, addressing the limitations of current osteoconductive substitutes.

JP7596315B2Active Publication Date: 2024-12-09UNIVERSITY OF HEIDELBERG +1
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2021572842
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-08-14
Publication Date
2024-12-09
Estimated Expiration
2040-08-14

AI Technical Summary

Technical Problem

Current bone substitutes, such as hydroxyapatite and calcium phosphate materials, primarily exhibit osteoconductive properties, failing to stimulate bone formation directly and often lose osteoinductive substances rapidly due to washout or degradation, leading to short-term effects and potential systemic issues.

Method used

A method involving the incorporation of strontium, fluorine, and/or gallium ions into apatite structures, particularly hydroxyapatite, by heating starting materials like portlandite, calcium oxide, aragonite, and calcite in an autoclave with a phosphate source, ensuring these ions are bonded within the crystal lattice for sustained osteoinductive and osteophilic properties.

Benefits of technology

The resulting osteophilic bone graft material maintains long-term osteoinductive effects at the implant site, promoting bone healing without systemic impact, and demonstrates enhanced alkaline phosphatase activity and cell protein production in human osteoblasts, indicating improved bone formation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007596315000009
    Figure 0007596315000009
  • Figure 0007596315000010
    Figure 0007596315000010
  • Figure 0007596315000011
    Figure 0007596315000011
Patent Text Reader

Abstract

The present invention relates to a method for producing a bone-compatible bone substitute from a starting material substantially comprising portlandite, calcium oxide, aragonite, calcite, and / or apatite. The starting material is introduced into an autoclave together with a strontium, fluorine, and / or gallium source. When using a starting material substantially comprising portlandite, calcium oxide, aragonite, and calcite, a phosphate source is also introduced. Furthermore, H2O is added to the autoclave as part of the solvent to adjust the pH value inside the autoclave to a range greater than 7. The sealed and filled autoclave is then heated for at least 1 hour and then cooled. The bone-compatible bone substitute thus developed is then washed from residues of the phosphorus, strontium, fluorine, and / or gallium sources. Furthermore, the present invention relates to a bone-compatible bone substitute substantially consisting of apatite, in which strontium ions are incorporated into the crystal lattice.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for producing osteotropic bone substitute materials from starting materials which essentially comprise portlandite, calcium oxide, aragonite, calcite (e.g. lime-coated algal skeletons) and / or apatite (e.g. present as hydroxyapatite, e.g. obtained from vertebrate bones or synthetic production).Furthermore, the present invention relates to osteotropic bone materials produced by the method according to the invention.

[0002] Within the context of the present invention, the starting materials described can also be understood to include future synthetically produced materials having similar structures to the starting materials. [Background technology]

[0003] Many currently used bone substitutes consisting of autologous, allogeneic or xenogeneic natural bone, coral or algae, used as bone implants or as bone substitutes within the framework of bone augmentation, or hydroxyapatite bone substitutes produced by completely synthetic means, have only osteoconductive properties. This means that the calcium phosphate or hydroxyapatite bone substitutes used so far have a biocompatible surface suitable for the direct growth of bone tissue on the implant surface, but do not directly stimulate the formation of new bone in the direct bone environment of the implant. Hydroxyapatite or calcium phosphate materials generally only have osteoconductive properties. They therefore enable bone growth, but do not themselves stimulate the proliferation or differentiation of cells that induce bone formation, such as osteoblasts or their precursor cells. In the sense of the present invention, direct growth can be understood in particular as growth without an "intermediate tissue layer" between the implant surface and the bone tissue.

[0004] To develop an osteoinductive effect, bone substitutes or organic substances (e.g. collagen or organic molecules) have traditionally been supplemented with further proteins, peptides or other molecules. Examples of this are growth factors (e.g. various BMPs, IGF1 / 2, FGF, etc.) or serum products. The problem with this is that the duration of these substances remaining in the implant or at the implant site is often unclear, since they are often quickly washed away or degraded from the implant site. As a result, on the one hand, osteoinductive properties are only present for a short time and therefore cannot really be added, and on the other hand, systemic effects in the whole organism, which are generally not intended, can occur.

[0005] Examples of methods for producing such bone substitutes can be taken from EP 230570 and EP 028074. In this case, a bone substitute consisting of hydroxyapatite derived from lime-coated seaweed is obtained by converting the naturally occurring calcium carbonate skeleton in a suitable manner.

[0006] However, as already mentioned, such bone replacement devices are merely osteoconductive and not osteoinductive.

[0007] Furthermore, it can be taken from P. Melnikov et al., Materials Chemistry and Physics 117(1), 86-90, (2009) (Gallium-containing hydroxyapatite for use in orthopedics), CN 101928136 (Fluorinated hydroxyapatite and its use for the manufacture of artificial bone), and EP 2228080 (Gallium-doped calcium phosphonate compounds with apatite structure for filling dental and bone defects). [Prior art documents] [Patent documents]

[0008] [Patent Document 1] European Patent No. 230570 [Patent Document 2] European Patent No. 028074 [Patent Document 3] China Patent Application Publication No. 101928136 [Patent Document 4] European Patent Application Publication No. 2228080 [Non-patent literature]

[0009] [Non-Patent Document 1] P.Melnikov et al.,Materials Chemistry and Physics 117(1),86-90,(2009) Summary of the Invention [Problem to be solved by the invention]

[0010] It is therefore an object of the present invention to provide a method for producing a bone substitute having long-term activity and localized osteophilic properties, and the bone substitute itself. [Means for solving the problem]

[0011] According to the invention, this object is achieved by a method for producing a bone-compatible bone substitute having the features of claim 1 and by a bone-compatible bone substitute having the features of claim 15 .

[0012] Advantageous embodiments of the invention are set forth in the dependent claims. [Brief description of the drawings]

[0013] [Figure 1] A graph showing the results of the comparative test (results of alkaline phosphatase in "1. Test"). [Diagram 2] A diagram showing the results of the comparative test (cell division / cell protein results in "1. Test"). [Diagram 3] A graph showing the results of the comparative test (results of alkaline phosphatase in "2. Test"). [Figure 4] A diagram showing the results of the comparative test (cell division / cell protein results in "2. Test"). [Diagram 5] A graph showing the results of the comparative test (results of alkaline phosphatase in "3. Test"). [Figure 6] A diagram showing the results of the comparative test (cell division / cell protein results in "3. Test"). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] According to the invention, it is provided that a starting material is used that essentially comprises portlandite, calcium oxide, aragonite, calcite and / or apatite (e.g. present as hydroxyapatite). The starting material is introduced into an autoclave together with a strontium, fluorine and / or gallium source, where, when using a starting material that essentially comprises portlandite, calcium oxide, aragonite, calcite, a phosphate source is introduced. In the case of a starting material that essentially consists of apatite, a phosphate source can also be introduced, but this is not necessary. Furthermore, water is added to the autoclave as part of the solvent. Then, at room temperature and normal pressure, the pH value in the autoclave is brought to a range above 7. The closed and filled autoclave is then heated for at least 1 hour and subsequently cooled. Finally, the contents of the autoclave are washed from residues of strontium, fluorine and / or gallium sources. The same applies when a phosphorus source is used.

[0015] According to the invention, it has been realised that inter alia strontium, fluorine and / or gallium ions incorporated into the apatite structure have osteoinductive or rather osteophilic or anti-resorptive properties.

[0016] An essential aspect of the invention is the method according to the invention for incorporating strontium, fluorine and / or gallium ions into apatite, in particular into the hydroxyapatite structure, rather than simply attaching them in a suitable manner. In the case of merely superficial attachment, separation of the attached material may occur. However, the method according to the invention allows the abovementioned ions, which have osteocompatible, i.e. osteoinductive, anti-resorbing properties and / or promote the formation of bone tissue, to be bound to the developing apatite structure in such a way that they cannot be easily separated.

[0017] For the successful conversion of starting materials consisting of calcium carbonate materials (i.e. especially portlandite, calcium oxide, aragonite, calcite) into apatite or rather hydroxyapatite structures, the presence of a phosphate source is essential, in which case other phosphates can be used. When using apatite materials (e.g. vertebrate bones) as starting materials, the presence of a phosphate source is not necessarily necessary, but has proven to be advantageous. In particular, this prevents the weakening of existing structures during the process.

[0018] According to the tests on which the present invention is based, particularly good results can be achieved if the closed and filled autoclave is heated to a temperature of at least 30°C, preferably above 190°C. This can be done in an oven or in a heating module. It is also possible to provide a heating module integrated with the autoclave. At these temperatures, a sufficiently good conversion of the starting material into doped apatite is achieved, and, as already mentioned, the aforementioned ions are also incorporated and bound to the crystal lattice of the apatite. The lower the oven temperature, the slower the reaction takes place in the autoclave.

[0019] Within the meaning of the method according to the invention, a heating cabinet or the like can also be called an oven. Important in this connection is the fact that the device is able to maintain the desired temperature, between 30 and several hundred degrees, at a constant level for a longer period of time.

[0020] To clean the contents of the autoclave from residues of strontium, fluorine and / or gallium sources and phosphorus sources, different methods are possible. Depending on the choice of sources, the contents of the autoclave can be cleaned mechanically, preferably with a filter device. This is the case when sources that are as large as possible or have low solubility are used.

[0021] For good tissue tolerance of the bone substitute according to the invention, it is advantageous, in particular following cleaning of a mechanical nature, to wash the contents of the autoclave until a pH value of less than 8 is reached.

[0022] An alkaline solution (especially an ammonia solution) can be used to bring the pH value before closing the autoclave to a range above 7. For example, an ammonium dihydrogen phosphate solution or another phosphate compound can also be used for this purpose.

[0023] Preferably, the introduction of the strontium, fluorine and / or gallium sources is carried out in excess relative to the starting material. Advantageously, this also applies to the phosphate source. In other words, a large reservoir of each material is made available so that good incorporation into the apatite crystal lattice can be achieved with high certainty. In the final, aforementioned washing step, unused starting material of each of the strontium, fluorine and / or gallium sources and the phosphorus source is removed from the produced material. This means that the material is cleaned.

[0024] If, for example, ammonium dihydrogen phosphate or diammonium phosphate is used as the phosphorus source, this can be used at the same time to achieve the desired pH value. It has also been found that the use of ammonium dihydrogen phosphate dissolved in water is particularly easy to add and that an optimal reaction environment can be achieved in the autoclave.

[0025] Preferably, in the total mixture during autoclaving, calcium and phosphorus atoms are present in a ratio not exceeding 10: 5. Such a ratio has proven to be advantageous for the osteophilic properties of the resulting bone substitute, since the respective osteophilic, i.e. osteoinductive and / or anti-resorptive, substances are present in a ratio which gives particularly good results.

[0026] As apatite, for example, vertebrate or mammalian bones can be used. Mammalian bones (e.g. from bovine or porcine animals) already provide apatite as a significant proportion of hydroxyapatite and carbonate apatite. On the other hand, as starting materials, aragonite or calcite, calcareous algal skeletons or other calcium carbonate substances in burned, unburned and / or chemically treated form can also be used. When using vertebrate or mammalian bones, these are advantageously subjected to conventional pyrolysis or chemical maceration, i.e. removal of immunogenic substances.

[0027] Basically, it is preferable to heat the closed and filled autoclave for a longer period. According to the present invention, very good results of the developing bone-compatible bone substitute are achieved after 1-4 days, and it has been found that heating for a very long period does not necessarily bring significantly better results.

[0028] As already mentioned, after heating in an autoclave and subsequent cooling, the strontium, fluorine and / or gallium source is separated from the obtained bone-compatible bone substitute by washing the latter. Preferably, as the strontium, fluorine and / or gallium source, a material that is easy to wash off or has low water solubility is used. The use of a material that is easy to wash off has the advantage that when washing the produced bone-compatible bone substitute, it can be easily washed off, and therefore the bone-compatible bone substitute can be washed more easily. Alternatively, a material that is less soluble (especially coarsely crystalline) has the advantage that during the conversion process in an autoclave, a sufficient amount of strontium, fluorine and / or gallium ions are available, while the subsequent washing can be carried out in a particularly easy manner, for example also mechanically.

[0029] Particularly easy cleaning of the resulting bone-compatible bone substitute can be achieved if the strontium, fluorine and / or gallium sources are added to the autoclave as solids in a container, the container being designed to allow the exchange of ions of the strontium, fluorine and / or gallium sources with the solvent present in the autoclave while retaining the solids. This obviously facilitates the final cleaning of the resulting bone-compatible bone substitute.

[0030] Before or after introduction into the autoclave, the starting material and / or the contents of the autoclave are preferably subjected to pyrolysis and / or chemical cleaning after the completion of the method.The pyrolysis and chemical cleaning methods each have the advantage that potentially existing proteins or other organic foreign substances are removed from the produced osteocompatible bone substitute, so that the interaction occurring during implantation of the bone substitute in the human body is minimized or eliminated.

[0031] Furthermore, the present invention relates to a bone-compatible bone substitute produced by the method according to the present invention. The bone-compatible bone substitute substantially comprises apatite and contains strontium, fluorine and / or gallium ions in its crystal lattice. These ions are capable of being absorbed in the animal or human body. After implantation into the bone, the bone-compatible properties are developed. In addition to apatite (more specifically hydroxyapatite), small amounts of calcium phosphate, calcite, aragonite and tricalcium phosphate may also be present. According to the present invention, the median concentration of ions exceeds the median concentration of about 0.51-0.60 wt. % for strontium ions, which is in accordance with established bone substitutes. Established bone substitute materials are vertebrate or mammalian bone (BioOss® (Geistlich®), The Graft® (Regedent®), MinerOss® XP (Camlog® / BioHorizons®): approx. 0.51-0.56% by weight), lime-covered algae (Algipore® (Symbios®): approx. 0.60% by weight) or natural bone of vertebrates or mammals (bovine: approx. 0.58% by weight), depending in particular on impurities, additional feeding or different geological-regional conditions. According to the invention, the medium concentration of strontium ions in this case is at least 0.65% by weight, preferably 0.75% by weight and in particular more than 1.0% by weight.

[0032] The osteophilic bone substitute according to the invention produced according to the method according to the invention can be used, for example, for the production of dimensionally stable blocks, into which dental cylinder implants or other metal bodies are also integrated. These blocks can be implanted in the jawbone in the future as dental implant supports and, following a healing phase of 3-6 months, can be used directly without the need for further secondary interventions. Due to the fact that the osteophilic bone substitute obtained has a powder-like form, the dimensionally stable blocks produced therefrom can be made to size and thereby adapted to bone defects such as missing teeth.

[0033] As a result of the implantation of strontium, fluorine and / or gallium ions according to the invention, the bone substitute develops a local osteotropic effect that occurs essentially only at the implant site and therefore does not have a systemic effect.

[0034] Another advantage is that the bone substitute according to the invention develops its osteoinductive or osteophilic effect throughout the entire period it remains at the implantation site and ceases to do so as soon as it is replaced by autologous bone tissue, thus achieving a faster and more sustainable bone healing of the bone defect.

[0035] Another application of the osteocompatible bone substitute according to the present invention may be the stabilization of osteoporosis, traumatic and / or malignant related vertebral fractures or vertebral compression fractures. Another possibility is to use the material produced according to the present invention as starting material for 3-D printing processes.

[0036] The invention is explained in more detail below by means of schematic exemplary embodiments with reference to the drawings.

[0037] Manufacturing method Below, an exemplary production of the bone-compatible bone substitute material according to the present invention, carried out according to the method according to the present invention, is described.

[0038] For this purpose, a Teflon container with a volume of 150 ml is used, which is filled with the following substances:

[0039] [Table 1]

[0040] As starting material, the skeleton of a lime-covered alga is used as an example of aragonite. When using starting materials containing CO2, it is usually advantageous to burn them, whereby it is desirable to preserve the outer structure of the material. However, as described, the method according to the invention can also be applied to apatite materials (e.g. from vertebrate bone as starting material), in which case the presence of a phosphate source proves to be advantageous on the one hand for the introduction of bone-affinity ions, but on the other hand for preserving the structure of the starting material.

[0041] Prior to being added to the Teflon container, the algae skeleton is cauterized to remove foreign proteins, proteins, etc. Ammonium dihydrogen phosphate, strontium fluoride, potassium fluoride and 25% ammonia solution are then added. Deionized water is also added.

[0042] The respective weights or respective volumes of the substances added can be found in the table.

[0043] In this case, ammonium dihydrogen phosphate serves as the phosphate source, although other phosphate sources are possible as described. Strontium fluoride is used as the strontium source and also as the fluoride source. Potassium fluoride is also used as a fluoride source.

[0044] The substance is introduced into the Teflon container, possible gas formation is awaited, and then the container is closed. The Teflon container is then placed in an autoclave, for example a pressurized decomposition container. This container is preferably made of stainless steel. The cover is then screwed tightly onto the autoclave.

[0045] The corresponding pressure decomposition vessel, tightly closed, is then placed in a preheat cabinet or heating block having a temperature of 190°C.

[0046] The pressure decomposition vessel remains in the heating cabinet for five days, during which time the temperature of 190°C is maintained. After this time, the heating cabinet is turned off. The pressure decomposition vessel is then allowed to cool slowly in the heating cabinet or heating block. This takes approximately one day.

[0047] After cooling completely, open the pressure decomposition vessel and the Teflon vessel, and wash the obtained bone affinity bone substitute.For this purpose, the bone affinity bone substitute is poured on a filter paper together with water and washed.Some washing process, for example, rinsing process, is carried out until a pH value of less than 8 is reached.

[0048] The osteocompatible bone substitute is then again introduced into the heating cabinet, but only dried at 40°C.

[0049] The osteocompatible bone substitute is then ready for further use, for example it can then be molded into a desired shape and sterilized.

[0050] Tests and Results The effect of the new bone-compatible bone substitute material prepared according to the method of the present invention is described in more detail below, and the bone induction effect is demonstrated based on the test results.The results show that the use of the bone substitute material of the present invention will further stimulate the local formation of new bone in bone defects, due to the fact that alkaline phosphatase, the most important bone formation marker in human bone cells, is stimulated.

[0051] An in vitro test using primary human osteoblasts was carried out to test the direct effect of the bone-compatible bone substitute of the present invention when contacting primary human cells, in order to avoid overlooking the detrimental effect of the bone-compatible bone substitute of the present invention on human bone cells, such as cell death.

[0052] Therefore, prior to the clinical use of new bone substitutes in vivo, primary human osteoblasts are suitable as a sensitive test system to investigate the effects of new bone substitutes on human bone cell metabolism.

[0053] In vitro cells (such as primary human bone cells) have four possible response modes: No response at all Apoptosis (cell death) Increase / decrease in cell division Increased / decreased production of differentiation cell products (e.g. alkaline phosphatase in the case of osteocytes) required for the deposition of new bone tissue in vivo and for mineralization and formation of hydroxyapatite.

[0054] To carry out the test, a co-culture of primary human bone cells was used. To compare the effects, a commercially available bone substitute and an osteocompatible bone substitute produced according to the method of the present invention were used. In the in vitro experiment, the following bone substitutes were comparatively tested with respect to their effects on primary human bone cells: 1. BioOss® (bovine bone granules, commercially available from Geistlich Biomaterials) 2. Algipore® (available from Dentsply, based on European Patent No. 230570) 3. New Algipore1 (=NA1) Bone-compatible bone substitute material according to the present invention 4. New Algipore2 (NA2) Bone-compatible bone substitute material according to the present invention 5. New BioOss1 (BioOss® subjected to the method of the invention)

[0055] [Table 2]

[0056] To investigate the effect of the above materials on the cellular functions of primary human bone cells, the following evaluation methods were selected: A alkaline phosphatase B cellular proteins

[0057] 1. Testing Alkaline phosphatase Comparative results are expressed as % of control + / - standard deviation. Initially, the activity of alkaline phosphatase was tested in the culture medium supernatant after the culture of human bone cells in the presence of various substances. As a control, an aliquot of cell culture growth medium used alone, without cells, was used. This is because, despite a serum-free rinse before exposing the cells to the materials, the cavities of the culture plates always contain residues of serum contained in the culture medium. Serum also always contains small amounts of alkaline phosphatase. In this first test New BioOss1 was not yet available.

[0058] [Table 3]

[0059] These results are shown graphically in FIG.

[0060] interpretation While BioOss® tends to reduce the activity of the enzyme alkaline phosphatase, which is essential for bone formation and mineralization in human bone cells, the bone filler of the present invention results in a highly significant increase in the activity of alkaline phosphatase secreted by human bone cells.

[0061] Therefore, bone-specific alkaline phosphatase, the most important osteoblast marker protein, is stimulated to a significantly greater extent in a human bone cell model by the bone substitute material according to the present invention than in the presence of conventional materials.The difference in the effectiveness of NA1 and NA2 in alkaline phosphatase activity is likely due to the increased fluoride and strontium content in NA2 compared to NA1.

[0062] When measuring alkaline phosphatase activity in cell culture supernatants, it must be taken into account that in vivo mineral or bone formation occurs extracellularly due to secretion of alkaline phosphatase into the osteoblast microenvironment.

[0063] Cell division / cell proteins As an indicator of the effect of the bone filler on cell division, the protein content in the individual "cavities", i.e. in the reaction chambers of the used perforated plates, was analyzed. For this, Triton extracts of the respective cavities were used to determine the protein content according to the BCA method. The higher the protein content in the individual cavities, the more protein material corresponding cellular material must be present in the cavity. This means that the bone cells are always the same size and the number of cells has increased, since proteins are not stored in large quantities inside the bone cells. Thus, a decrease in the protein content in the cell culture cavities, i.e. in the reaction chambers, is equal to a decrease in the number of cells adhering on the cell culture base or on the bone filler (apoptotic cells, i.e. dead cells, do not remain attached and are washed away before the addition of Triton). The results are again shown as % of control + / - standard deviation.

[0064] [Table 4]

[0065] These results are shown graphically in FIG.

[0066] interpretation There are no differences between the tested materials regarding the cellular protein content in the cell culture cavity, therefore the materials have no effect on cell division or cell death, since apoptotic cells do not remain attached but detach and are washed away prior to the assay procedure.

[0067] big picture These observations indicate that the material obtained according to the method of the present invention has a very positive effect on alkaline phosphatase activity in human bone cells, which is consistent with the very favorable and sustained effect of the bone substitute material of the present invention in stimulating bone mineral formation in vivo, without cell division being affected (i.e. stimulated or inhibited).

[0068] 2. Testing, Activation of Conventional BioOss® Material by the Method of the Invention The BioOss® material, which has been used so far as a bone replacement material in dentistry and oral surgery, consists of the natural hydroxyapatite material of bovine animal mineral bone tissue. By means of the method according to the invention, even in the case of natural calcium phosphate crystal lattices, it is possible to carry out a partial exchange of calcium ions in the hydroxyapatite crystals with strontium and fluoride ions in a controlled manner. In this case, calcium and phosphorus atoms should be present in the total mixture of net weight autoclave in a ratio not exceeding 10:5.

[0069] In the following experiments with primary human osteoblasts, the effect of conventional BioOss® material on alkaline phosphatase activity is tested in parallel with the effect of BioOss1 material activated by the method of the present invention.

[0070] At the same time, in order to allow a ranking of the effectiveness of all materials produced by the method according to the invention in parallel test batches, the materials already tested above were also used in the same experiment, again with alkaline phosphatase activity measured in the cell culture supernatant after a 24 hour incubation period of the cells with the new material.

[0071] This experiment was performed again using primary human bone cells from a different individual than in the first experiment (1. Test).

[0072] Alkaline phosphatase

[0073] [Table 5]

[0074] These results are shown graphically in FIG.

[0075] Cell division / cell proteins

[0076] [Table 6]

[0077] These results are shown graphically in FIG.

[0078] interpretation While conventional BioOss® materials have no significant stimulatory effect on alkaline phosphatase activity in cell culture supernatants, as compared to human bone cells not in contact with the bone filler, BioOss® materials pretreated by the method according to the invention (BioOss1) result in almost double the alkaline phosphatase activity. Thus, the method according to the invention is also suitable for activating commercially available bovine hydroxyapatite materials, endowing BioOss® materials with osteoinductive properties, which were previously only osteoconductive.

[0079] Moreover, this test reproduces the results of the first test already analysed above: while the commercially available BioOss® does not show a substantial stimulation of alkaline phosphatase, BioOss1 produced by the method according to the invention shows an almost two-fold higher activation of alkaline phosphatase activity.Similarly, the "algal hydroxyapatite materials" NA1 and especially NA2 produced by the method according to the invention show an even stronger stimulation of alkaline phosphatase activity.

[0080] This comparative experiment again gave no reliable indication that the bone substitutes tested had a significantly different effect on total cellular protein production in the cell supernatant of the reaction chamber (see FIG. 4).

[0081] 3. Testing and replicating results In another batch, all experiments are repeated once again with different primary human osteoblasts from a third healthy donor, and the results are reproduced in a consistent manner. Thus, in this case, the effects of all materials produced so far according to the method of the present invention are reproduced again in parallel in another test batch and compared with the effects of commercially available bone substitutes.

[0082] Alkaline phosphatase

[0083] [Table 7]

[0084] These results are shown graphically in FIG.

[0085] Cell division / cell proteins

[0086] [Table 8]

[0087] These results are shown graphically in FIG.

[0088] interpretation This experiment also proves that the bone fillers NA2 and BioOss1 "activated" by the method of the present invention have a significantly stronger effect on stimulating alkaline phosphatase activity than the commercially available bone fillers BioOss® and Algipore®. The NA1 material treated with the initial process shows an effect comparable to the commercially available Algipore® bone filler.

[0089] As a result, all bone substitute materials "activated" by the manufacturing method of the present invention have been proven to be superior to previous products in terms of stimulating alkaline phosphatase, a standard osteoblast bone formation marker.

[0090] The production method according to the invention is therefore suitable for the production of activated bone substitutes by incorporating activating ions, such as strontium ions, into the crystal lattice during the conversion process of calcium carbonate or mixtures of portlandite, calcium oxide and calcite into apatite materials, and directly from existing hydroxyapatite materials. Within the framework of the invention, materials may in particular be considered as activated, which also have osteoinductive, osteophilic or anti-resorbing properties.

[0091] Thus, the method of the present invention and the bone-compatible bone substitute produced using the method of the present invention provide a material that has sustained and localized osteoinductive or osteocompatible properties and is highly suitable as an implant material in bone tissue.

Claims

1. 1. A method for producing a bone-compatible bone substitute from a starting material substantially comprising portlandite, calcium oxide, aragonite, calcite and / or apatite, comprising the steps of: said portlandite, calcium oxide, aragonite and / or calcite are used in the form of burned, unburned and / or chemically treated bioscaffolds, and / or the apatite used is vertebrate bone after pyrolysis or chemical maceration, The starting materials are introduced into an autoclave together with a source of strontium and / or gallium; When using a starting material that essentially comprises portlandite, calcium oxide, aragonite, or calcite, a phosphate source is introduced; H 2 O is added to the autoclave as part of the solvent; The pH value in the autoclave is set to a range exceeding 7, The closed and filled autoclave is heated for at least 1 hour and then cooled; A method in which the contents of the autoclave are subsequently washed from residues of the phosphorus, strontium and / or gallium sources.

2. 2. The method according to claim 1, characterized in that the closed and filled autoclave is heated to at least 30°C, preferably above 190°C.

3. 3. The method according to claim 1 or 2, characterized in that the contents of the autoclave are mechanically washed using a filter device.

4. The contents of the autoclave are heated with H2O until a pH of preferably less than 8 is reached. 2 4. The method according to claim 1, further comprising washing with O.

5. 5. The method according to claim 1, wherein an alkaline solution is used to bring the pH value in the autoclave to a range above 7.

6. 6. The method according to claim 1, wherein the strontium and / or gallium source is introduced in excess relative to the starting material.

7. 7. The method according to claim 1, wherein ammonium dihydrogen phosphate or diammonium phosphate is added as phosphorus source.

8. 8. The method according to claim 1, wherein the calcium and phosphorus atoms are present in the total mixture in a ratio not exceeding 10:5 (atomic ratio).

9. 9. The method according to any one of claims 1 to 8, characterized in that the closed and filled autoclave is heated for at least 12 hours.

10. 10. The method according to claim 1, wherein the strontium and / or gallium source is a material that is easy to wash off or has low water solubility.

11. the strontium and / or gallium source is added to the autoclave as a solid in a container; 11. A method according to any one of claims 1 to 10, characterized in that the vessel allows for exchange of ions of the strontium and / or gallium source with the solvent whilst retaining a solid material.

12. 12. A method according to any one of the preceding claims, characterized in that, before or after being introduced into the autoclave, the starting material and / or the contents of the autoclave are subjected to a pyrolysis treatment and / or a chemical cleaning method.

13. Substantially comprising apatite, Produced from portlandite, calcium oxide, aragonite and / or calcite in the form of burned, unburned and / or chemically treated bioscaffolds, and / or made from vertebrate bones after pyrolysis or chemical maceration, A bone-compatible bone substitute in which strontium and / or gallium ions are incorporated into the crystal lattice of the apatite.

Citation Information

Patent Citations

  • Method for preparing fluoridated hydroxyapatite and application thereof

    CN101928136A

  • Wire connecting apparatus

    EP0028074A1

  • Porous hydroxy apatite material

    EP0230570A1

  • Galliated calcium phosphate biomaterials

    EP2228080A1

  • Preparation of hydroxyl apatite material

    JP1989502812A